Evidence map›Paper›PMID 28968148›Full record

ArticleHuman vaccines & immunotherapeutics2018

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.

F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, Marie-Pierre Preziosi

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.Medical decision making : an international journal of the Society for Medical Decision Making · 2019
    Article
  15. Inhibitors of theProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. From vaccines to global health to vaccines.Human vaccines & immunotherapeutics · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

F Marc LaForcea Serum Institute of India Pvt. Ltd. , Pune , India.
Mamoudou Djingareyb Regional Office, World Health Organization (WHO) , Brazzaville , Congo.
Simonetta Vivianic Independent Consultant , Strove , Italy.
Marie-Pierre Preziosid WHO/HQ , Geneva , Switzerland.
Serum Institute of India (India) · INWorld Health Organization · CHWorld Health Organization Regional Office for Africa · CG

Funding

World Health Organization 001
6 · The paper itself

Abstract

The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVac

Indexed as

Africa South of the SaharaDisease EradicationEpidemicsHumansImmunity, HerdImmunization ProgramsInfantMeningitis, MeningococcalMeningococcal VaccinesNeisseria meningitidis, Serogroup AVaccinationVaccines, ConjugateMenAfriVacMeningococcal VaccinesVaccines, Conjugateconjugate vaccinesEpidemic meningitisherd protectionneisseria meningitidis

Identifiers

PMID28968148
PMCPMC5989906
OpenAlexW2763772789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.